The islet in humans with type 2 diabetes (T2DM) is characterized by islet amyloid derived from islet amyloid polypeptide (IAPP), a protein that is co-expressed and secreted with insulin. Human IAPP (hIAPP) has the propensity to form oligomers in solution. These oligomers appear to form in membranes inducing non selective membrane leakage, for example of Ca2+ into cytosol. In studies supported by this grant we established that ?-cell mass is decreased in humans with T2DM, with increased ?-cell apoptosis. We reproduced the islet and metabolic phenotype of T2DM in rodents over expressing human IAPP, and documented that the toxic form of IAPP oligomers form intracellularly within the secretory pathway leading to endoplasmic reticulum (ER) stress induced apoptosis as well as organelle (mitochondrial) damage. We have established that ?-cells in humans with T2DM are also characterized by intracellular formation of toxic hIAPP oligomers, leakage of Ca2+ into cytosol leading to hyperactivation of the Ca2+ sensitive protease calpain. Collectively these characteristics reproduce those in neurodegenerative diseases mediated by proteotoxicity of amyloidogenic proteins (e.g. Alzheimers). In the neurodegenerative diseases there is an increasing appreciation that proteotoxicity by amyloidogenic proteins is mediated in part through disruption of the cellular mechanisms that remove misfolded and aggregated proteins, the ubiquitin/proteosome system and autophagy. In the proposed studies we propose studies to address the following aims. 1) To establish the specific mechanisms by which IAPP oligomers induce ?-cell apoptosis and dysfunction. 2) To establish if the ubiquitin proteosome system to protect against proteotoxicty is impaired by hIAPP toxic oligomers, and if so through which mechanism(s). 3) To establish if autophagy, the cellular system for removal of toxic oligomers and damaged organelles, is disrupted by hIAPP toxic oligomers, and if so, through which mechanisms. This program of studies would allow us to shed light into the underlying cause of loss of ?-cells in humans, and to establish a rationale approach to preventing this.
More than 25 million Americans now have Type 2 diabetes. The complications arising from type 2 diabetes (blindness, early death through heart disease, loss of limb, kidney failure) are the single largest cost to the US health system. The present studies are targeted to establish a better understanding of the underlying cause of type 2 diabetes so that more rationale efforts can be used to prevent and treat it.
|Butler, Peter C (2016) Glucagon-like Peptide 1 Drugs as Second-line Therapy for Type 2 Diabetes. JAMA Intern Med 176:1-3|
|Gurlo, Tatyana; Costes, Safia; Hoang, Jonathan D et al. (2016) Î² Cell-specific increased expression of calpastatin prevents diabetes induced by islet amyloid polypeptide toxicity. JCI Insight 1:e89590|
|Gurlo, T; Rivera, J F; Butler, A E et al. (2016) CHOP Contributes to, But Is Not the Only Mediator of, IAPP Induced Î²-Cell Apoptosis. Mol Endocrinol 30:446-54|
|Kegulian, Natalie C; Sankhagowit, Shalene; Apostolidou, Melania et al. (2015) Membrane Curvature-sensing and Curvature-inducing Activity of Islet Amyloid Polypeptide and Its Implications for Membrane Disruption. J Biol Chem 290:25782-93|
|Satin, Leslie S; Butler, Peter C; Ha, Joon et al. (2015) Pulsatile insulin secretion, impaired glucose tolerance and type 2 diabetes. Mol Aspects Med 42:61-77|
|Mukherjee, Abhisek; Morales-Scheihing, Diego; Butler, Peter C et al. (2015) Type 2 diabetes as a protein misfolding disease. Trends Mol Med 21:439-49|
|Costes, Safia; Gurlo, Tatyana; Rivera, Jacqueline F et al. (2014) UCHL1 deficiency exacerbates human islet amyloid polypeptide toxicity in Î²-cells: evidence of interplay between the ubiquitin/proteasome system and autophagy. Autophagy 10:1004-14|
|Rivera, Jacqueline F; Costes, Safia; Gurlo, Tatyana et al. (2014) Autophagy defends pancreatic Î² cells from human islet amyloid polypeptide-induced toxicity. J Clin Invest 124:3489-500|
|Costes, Safia; Butler, Peter C (2014) Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes? Cell Metab 20:201-3|
|Saisho, Yoshifumi; Butler, Alexandra E; Manesso, Erica et al. (2013) Response to Comment on: Saisho et al. Î²-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care 2013;36:111-117. Diabetes Care 36:e112|
Showing the most recent 10 out of 52 publications